



## Indium 111 Ibritumomab Tiuxetan

Revised: November 15, 2023.

CASRN: 1607828-40-9

### Drug Levels and Effects

#### Summary of Use during Lactation

Information in this record refers to the use of indium 111 ibritumomab tiuxetan as a diagnostic agent. No information is available on the use of indium 111 ibritumomab tiuxetan during breastfeeding. Because of the long half-life of indium 111 and the potential for serious adverse reactions in nursing infants, the manufacturer recommends not administering the drug in women who wish to continue breastfeeding. If the drug is administered to a nursing mother, breastfeeding should be discontinued. No restrictions on holding the infant after administration of the drug are necessary.[1]

#### Drug Levels

Indium 111 decays by electron capture with 173 keV and 245 keV gamma emissions and a physical half-life of 2.8 days.[2]

#### Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

#### Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

#### References

1. Gulec SA, Siegel JA. Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres. *J Nucl Med* 2007;48:2080-6. PubMed PMID: 18006608.
2. Dilsizian V, Metter D, Palestro C, Zanzonico P. Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Material.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Final report submitted: January 31, 2019. 2019. Available at: <https://www.nrc.gov/docs/ML1903/ML19038A498.pdf>

## Substance Identification

### Substance Name

Indium 111 Ibritumomab Tiuxetan

### CAS Registry Number

1607828-40-9

### Drug Class

Breast Feeding

Lactation

Milk, Human

Radiopharmaceuticals

Indium Radioisotopes

Diagnostic Agents